Paradigm Biopharmaceuticals has completed enrolment ahead of schedule in its pivotal Phase 3 trial for Zilosul®, enrolling 538 patients with knee osteoarthritis and maintaining its timeline for interim and final results.
- Enrolment exceeds target with 538 participants
- Phase 3 trial spans 65 sites across four countries
- Interim analysis set for September 2026
- Top-line results expected in Q1 2027
- Trial aims to confirm non-opioid pain treatment efficacy
Enrolment Milestone Reduces Phase 3 Execution Risk
Paradigm Biopharmaceuticals (ASX:PAR) has cleared a major hurdle in its Phase 3 PARA_OA_012 trial by completing enrolment with 538 participants, surpassing its initial target of 466. This global study, investigating Zilosul® (injectable pentosan polysulfate sodium) for knee osteoarthritis pain, now advances with reduced operational risk as it moves toward critical clinical readouts.
The trial's scale is notable: 65 clinical sites across Australia, the US, Hong Kong, and Moldova are involved, making it Paradigm's largest clinical undertaking to date. The expanded enrolment reflects ethical commitments to allow patients already in screening to complete the process, enhancing the robustness of the dataset.
Trial Design Targets Meaningful Clinical Outcomes
PARA_OA_012 is a randomised, double-blind, placebo-controlled study focused on evaluating the efficacy and safety of Zilosul® in knee OA patients. The primary endpoint measures changes in Weekly Average Daily Pain at Day 112, complemented by secondary endpoints assessing physical function and patient global assessment among other clinically meaningful outcomes.
Completion of enrolment enables Paradigm to concentrate on treatment completion and patient follow-up, with the interim analysis on track for September 2026. This analysis will review data from the first half of participants reaching their 112-day assessment, independent of enrolment status, keeping the trial on schedule for top-line results in the first quarter of 2027.
Addressing a Large Unmet Medical Need in Osteoarthritis
Osteoarthritis affects over 500 million people globally and remains a leading cause of disability. Current treatments largely manage symptoms without altering disease progression, leaving a gap for effective, safe, non-opioid therapies. Paradigm aims to fill this gap with Zilosul®, which has previously shown promising improvements in pain, function, and biological markers linked to OA progression.
Executive Chairman Paul Rennie emphasised the significance of this milestone, highlighting the dedication behind executing a complex global trial and the potential for Zilosul® to become an important treatment option for knee OA patients. The company now anticipates multiple upcoming catalysts, including the interim analysis and final Phase 3 results.
Upcoming Catalysts and Investor Engagement
Paradigm has already passed key milestones such as the 50% dosing mark and a 20% safety review with no material concerns. The next major steps include the interim analysis in Q3 2026 and the primary endpoint readout expected in Q1 2027.
To update investors, Paradigm will hold a webinar on 18 June 2026, offering insights into the Phase 3 program and forthcoming milestones. This engagement reflects the company’s commitment to transparency as it advances toward potential regulatory and commercial milestones.
Bottom Line?
With enrolment complete and timelines intact, Paradigm is poised for pivotal data releases that will test Zilosul®’s promise as a non-opioid osteoarthritis therapy.
Questions in the middle?
- Will the interim analysis confirm early signals of efficacy and safety for Zilosul®?
- How might Paradigm position Zilosul® commercially if Phase 3 results meet expectations?
- What regulatory pathways will Paradigm pursue following the top-line data in early 2027?